Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CJEU Opinion Backs Lundbeck Fine Over Citalopram ‘Pay For Delay’ Deals

Fine Of Almost €94m Should Be Upheld, Advocate General Recommends

Executive Summary

A CJEU advocate general has backed a European Commission fine of almost €94m imposed on Lundbeck over “pay for delay” deals struck with four generics firms over citalopram.

You may also be interested in...



Teva Will Rebut Latest EU Competition Criticism

In the wake of the European Commission issuing Teva with a supplementary statement of objections over a historical “pay for delay” patent settlement agreement on modafinil with Cephalon, the Israeli firm has insisted on its right to reply.

CJEU Confirms Settlements Can Break EU Law

The UK’s Competition and Markets Authority has welcomed a formal ruling by the CJEU that settling patent disputes can break EU law by restricting competition and abusing a dominant position, in a case revolving around so-called ‘pay for delay’ settlements over GSK’s Seroxat paroxetine antidepressant.

Patent Settlements May Break EU Law

Patent-litigation settlements reached almost 20 years ago in the UK over GSK’s Seroxat paroxetine antidepressant may contravene EU competition law, an advocate general has advised the CJEU.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB149953

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel